

REMAP-CAP Investigators - *NEJM* 2021 (Published: Feb 25, 2021)

Study Design	Multicenter, international, multifactorial, adaptive, platform double-blind, placebo, RCT – Critical COVID-19 – (1:1:1)
Location	Global – 49 hospitals
Inclusion	Critically ill COVID-19 pneumonia + admitted to the ICU and receiving respiratory or cardiovascular support
Exclusion	Imminent death or REMAP-CAP within 90 days
Intervention	Tocilizumab 8 mg/kg IV (up to 800 mg) or Sarilumab 400 mg
Control	Placebo

	Tocilizumab n=353	Sarilumab n=48	Control n=402
Primary Outcomes			
Organ support-free days, median	10***	11***	0
In-hospital Death	28%***	22%***	36%
Median number of days free of organ support in survivors	14	15	13
Comments: *** Probability of superiority to control, 99.5% or higher No biomarker driven decision OSFDs – organ support free days (composite ordinal outcome, all deaths within hospital are assigned the worst outcome [-1]). Corticosteroids within 7 days prior to first dose was 80% in the toci arm and 87.5% in the control arm.			
Abbreviations: ICU, intensive care unit			